Aimmune to Present at RBC Capital Markets Global Healthcare Conference
May 16 2019 - 8:30AM
Business Wire
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a
biopharmaceutical company developing treatments for
life-threatening food allergies, today announced that its Chief
Financial Officer, Eric Bjerkholt, will present at the RBC Capital
Markets Global Healthcare Conference on Tuesday, May 21, 2019, at
2:35 p.m. E.T. in New York City.
A live webcast of the presentation will be accessible on the
Events page under the Investor Relations section of the Aimmune
website at www.aimmune.com. A replay will also be available
following the webcast.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a biopharmaceutical company
developing oral treatments for life-threatening food allergies. The
company’s Characterized
Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to
provide meaningful levels of protection against allergic reactions
resulting from exposure to food allergens by desensitizing patients
with defined, precise amounts of key allergens. Aimmune’s first
investigational biologic product, AR101, is being developed as a
treatment to reduce the frequency and severity and adverse events,
including anaphylaxis, following exposure to peanut. The BLA for
AR101 is under review by the FDA, which in 2015 granted AR101
Breakthrough Therapy Designation for the desensitization of
peanut-allergic patients 4 to 17 years of age. Aimmune expects to
file for marketing approval of AR101 in Europe in mid-2019. Aimmune
has filed an IND application for its second product, AR201 for the
treatment of egg allergy, and intends to start a randomized phase 2
clinical trial in mid-2019. For more information, please see
www.aimmune.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190516005267/en/
Investors:Eric Bjerkholt(650) 376-5582
orebjerkholt@aimmune.comMedia:Jerica Pitts(312) 858-3469
orjpitts@w2ogroup.com
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Apr 2023 to Apr 2024